Alopecia areata treatment with baricitinib: different relapse phenotypes
J Dermatolog Treat. 2024 Dec;35(1):2324832. doi: 10.1080/09546634.2024.2324832. Epub 2024 Mar 11.NO ABSTRACTPMID:38465657 | DOI:10.1080/09546634.2024.2324832 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - March 11, 2024 Category: Dermatology Authors: Federica Dall'Oglio Maria Rita Nasca Francesco Lacarrubba Pasquale Vitale Giuseppe Micali Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Alopecia areata treatment with baricitinib: different relapse phenotypes
J Dermatolog Treat. 2024 Dec;35(1):2324832. doi: 10.1080/09546634.2024.2324832. Epub 2024 Mar 11.NO ABSTRACTPMID:38465657 | DOI:10.1080/09546634.2024.2324832 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - March 11, 2024 Category: Dermatology Authors: Federica Dall'Oglio Maria Rita Nasca Francesco Lacarrubba Pasquale Vitale Giuseppe Micali Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
Paediatr Drugs. 2024 Mar 11. doi: 10.1007/s40272-024-00620-2. Online ahead of print.ABSTRACTAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with ...
Source: Paediatric Drugs - March 11, 2024 Category: Pediatrics Authors: Linnea L Westerkam Diana B McShane Elizabeth L Nieman Dean S Morrell Source Type: research
Treatment Options for Alopecia Areata in Children and Adolescents
AbstractAlopecia areata (AA) lifetime incidence is around 2%, with many patients first experiencing symptoms during childhood. However, ritlecitinib is the only FDA-approved treatment for pediatric patients 12 years and older. This review outlines reported topical, injectable, and oral treatment options for pediatric patients with AA. Clinical studies were obtained via a PubMed search using the following search terms: alopecia areata, areata, universalis, or totalis and medication, therapy, treatment, drug, or management. Only studies with pediatric patients were included in this review. Commonly used therapies, including ...
Source: Pediatric Drugs - March 11, 2024 Category: Pediatrics Source Type: research
Review of global epidemiology data for Alopecia Areata highlights gaps and a call for action
Br J Dermatol. 2024 Mar 1:ljae088. doi: 10.1093/bjd/ljae088. Online ahead of print.NO ABSTRACTPMID:38426530 | DOI:10.1093/bjd/ljae088 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2024 Category: Dermatology Authors: Cathryn Sibbald Leslie Castelo-Soccio Source Type: research
Review of global epidemiology data for Alopecia Areata highlights gaps and a call for action
Br J Dermatol. 2024 Mar 1:ljae088. doi: 10.1093/bjd/ljae088. Online ahead of print.NO ABSTRACTPMID:38426530 | DOI:10.1093/bjd/ljae088 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2024 Category: Dermatology Authors: Cathryn Sibbald Leslie Castelo-Soccio Source Type: research
Review of global epidemiology data for Alopecia Areata highlights gaps and a call for action
Br J Dermatol. 2024 Mar 1:ljae088. doi: 10.1093/bjd/ljae088. Online ahead of print.NO ABSTRACTPMID:38426530 | DOI:10.1093/bjd/ljae088 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2024 Category: Dermatology Authors: Cathryn Sibbald Leslie Castelo-Soccio Source Type: research
Review of global epidemiology data for Alopecia Areata highlights gaps and a call for action
Br J Dermatol. 2024 Mar 1:ljae088. doi: 10.1093/bjd/ljae088. Online ahead of print.NO ABSTRACTPMID:38426530 | DOI:10.1093/bjd/ljae088 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2024 Category: Dermatology Authors: Cathryn Sibbald Leslie Castelo-Soccio Source Type: research
Review of global epidemiology data for Alopecia Areata highlights gaps and a call for action
Br J Dermatol. 2024 Mar 1:ljae088. doi: 10.1093/bjd/ljae088. Online ahead of print.NO ABSTRACTPMID:38426530 | DOI:10.1093/bjd/ljae088 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - March 1, 2024 Category: Dermatology Authors: Cathryn Sibbald Leslie Castelo-Soccio Source Type: research
